Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)

Molecular MRD status and outcome after transplantation in NPM1-mutated AML

(2020) Richard Dillon et al.   BLOOD

NARASIMHA: Novel Assay based on Targeted RNA Sequencing to Identify ChiMeric Gene Fusions in Hematological Malignancies

(2020) Nikhil Patkar et al.   Blood Cancer Journal

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia

(2020) Jennifer M. Yoest et al.   Frontiers in Cell and Developmental Biology

Machine learning derived genomics driven prognostication for acute myeloid leukemia with RUNX1-RUNX1T1

(2020) Anam Fatima Shaikh et al.   LEUKEMIA & LYMPHOMA

NGS‐Defined Minimal Residual Disease Before Stem Cell Transplantation Predicts Acute Myeloid Leukemia Relapse

(2019) Richard D. Press et al.   AMERICAN JOURNAL OF HEMATOLOGY

getITD for FLT3-ITD-based MRD monitoring in AML

(2019) Tamara J. Blätte et al.   LEUKEMIA

Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context

(2019) Nikhil Patkar et al.   Frontiers in Oncology

Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group

(2019) Frank G. Rücker et al.   BLOOD

A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1

(2019) Nikhil Patkar et al.   Blood Cancer Journal

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease

(2019) Christopher S. Hourigan et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

(2018) Mojca Jongen-Lavrencic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

(2018) Felicitas Thol et al.   BLOOD

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia

(2018) Laura W. Dillon et al.   HAEMATOLOGICA

Mutation Clearance after Transplantation for Myelodysplastic Syndrome

(2018) Eric J. Duncavage et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia

(2018) Nikhil Patkar et al.   Oncotarget

Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes

(2017) Adam Waalkes et al.   HAEMATOLOGICA

Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations

(2017) Nuria Mencia-Trinchant et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes

(2017) Adam Waalkes et al.   HAEMATOLOGICA

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Assessment of Minimal Residual Disease in Standard-Risk AML

(2016) Adam Ivey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia

(2015) Jeffery M. Klco et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing

(2014) Stephen J Salipante et al.   MODERN PATHOLOGY

Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation

(2013) J. B. Hiatt et al.   GENOME RESEARCH

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease

(2013) A Kohlmann et al.   LEUKEMIA

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group

(2012) M. R. Loken et al.   BLOOD

The Use and Interpretation of Competing Risks Regression Models

(2012) J. J. Dignam et al.   CLINICAL CANCER RESEARCH

Detection of ultra-rare mutations by next-generation sequencing

(2012) M. W. Schmitt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

(2011) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of multiparameter flow cytometry for disease monitoring in AML

(2010) Wolfgang Kern et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia

(2010) F. Buccisano et al.   BLOOD

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML

(2009) S. Schnittger et al.   BLOOD